{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:01:01Z","timestamp":1772776861837,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.transproceed.2019.09.014","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:49:57Z","timestamp":1581122997000},"page":"657-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report"],"prefix":"10.1016","volume":"52","author":[{"given":"I.","family":"Soellradl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kehrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cejka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2019.09.014_bib1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation.","volume":"367","author":"Euvrard","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.09.014_bib2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00007890-200405150-00002","article-title":"Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice","volume":"77","author":"Koehl","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2019.09.014_bib3","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(00)02298-4","article-title":"Cancer risk in patients on dialysis and after renal transplantation","volume":"355","author":"Birkeland","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2019.09.014_bib4","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/jid.2015.312","article-title":"Melanoma risk and survival among organ transplant recipients","volume":"135","author":"Robbins","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.transproceed.2019.09.014_bib5","doi-asserted-by":"crossref","first-page":"15375","DOI":"10.18632\/oncotarget.23841","article-title":"Cancer risks in recipients of renal transplants: a meta-analysis of cohort studies","volume":"9","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.transproceed.2019.09.014_bib6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.transproceed.2019.09.014_bib7","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl. 6","key":"10.1016\/j.transproceed.2019.09.014_bib8","doi-asserted-by":"crossref","first-page":"vi379","DOI":"10.1093\/annonc\/mdw379.02","article-title":"Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma","volume":"27","author":"Hamid","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.transproceed.2019.09.014_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.transproceed.2019.09.014_bib10","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1600-6143.2005.00823.x","article-title":"CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance","volume":"5","author":"Li","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.09.014_bib11","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2019.09.014_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of Anti\u2013PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2019.09.014_bib13","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1097\/TXD.0000000000000814","article-title":"Liver allograft failure after nivolumab treatment \u2013 a case report with systematic literature research","volume":"4","author":"Gassmann","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.transproceed.2019.09.014_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519307481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134519307481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:33:38Z","timestamp":1758576818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134519307481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0041134519307481"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.09.014","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2019.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}